$1.77
0.052.91%
At close: -
$1.81
0.042.26%
After Hours: 4:04 PM EDT
Comments
Loading...
Maravai LifeSciences Analyst Ratings and Price Targets | NASDAQ:MRVI | Benzinga
Maravai LifeSciences Holdings Inc has a consensus price target of $11.15 based on the ratings of 15 analysts. The high is $35 issued by Goldman Sachs on July 14, 2022. The low is $2.5 issued by UBS on March 21, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, UBS, and B of A Securities on March 25, 2025, March 21, 2025, and March 3, 2025, respectively. With an average price target of $5.17 between Morgan Stanley, UBS, and B of A Securities, there's an implied 185.45% upside for Maravai LifeSciences Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
UBS
B of A Securities
Baird
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Maravai LifeSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 176.24% | Morgan Stanley | Tejas Savant50% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 38.12% | UBS | Dan Brennan65% | $8 → $2.5 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 341.99% | B of A Securities | Michael Ryskin46% | $9 → $8 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 65.75% | Baird | Catherine Schulte68% | $9 → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 12/05/2024 | Buy Now | 134.81% | Goldman Sachs | Matthew Sykes66% | $7 → $4.25 | Downgrade | Neutral → Sell | Get Alert |
| 11/14/2024 | Buy Now | — | Wolfe Research | Doug Schenkel71% | — | Initiates | → Peer Perform | Get Alert |
| 11/08/2024 | Buy Now | 618.23% | RBC Capital | Conor McNamara36% | $17 → $13 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | — | William Blair | Matt Larew20% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2024 | Buy Now | 397.24% | Baird | Catherine Schulte68% | $10 → $9 | Maintains | Outperform | Get Alert |
| 10/08/2024 | Buy Now | 286.74% | Goldman Sachs | Matthew Sykes66% | $8 → $7 | Maintains | Neutral | Get Alert |
| 08/27/2024 | Buy Now | 452.49% | Wells Fargo | Brandon Couillard70% | → $10 | Initiates | → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 728.73% | RBC Capital | Conor McNamara36% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 452.49% | Morgan Stanley | Tejas Savant50% | $11 → $10 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 341.99% | Goldman Sachs | Matthew Sykes66% | $7 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 507.73% | UBS | Dan Brennan65% | $8.5 → $11 | Maintains | Neutral | Get Alert |
| 07/09/2024 | Buy Now | 286.74% | Goldman Sachs | Matthew Sykes66% | $8 → $7 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 452.49% | Baird | Catherine Schulte68% | $8 → $10 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | 728.73% | Craig-Hallum | Christian Schwab70% | → $15 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | 673.48% | RBC Capital | Conor McNamara36% | $12 → $14 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 452.49% | Stifel | Daniel Arias78% | $11 → $10 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 341.99% | B of A Securities | Michael Ryskin46% | $10 → $8 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | 286.74% | Goldman Sachs | Matthew Sykes66% | $8 → $7 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 507.73% | Morgan Stanley | Tejas Savant50% | $12 → $11 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 562.98% | Morgan Stanley | Tejas Savant50% | $27 → $12 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 839.23% | Deutsche Bank | Justin Bowers52% | $23 → $17 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 894.48% | RBC Capital | Conor McNamara36% | $20 → $18 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 341.99% | Goldman Sachs | Matthew Sykes66% | $12 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 507.73% | Baird | Catherine Schulte68% | $18 → $11 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 507.73% | Credit Suisse | Dan Leonard57% | $14 → $11 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Keybanc | Paul Knight55% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 05/23/2023 | Buy Now | 673.48% | Credit Suisse | Dan Leonard57% | $18 → $14 | Downgrade | Outperform → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 618.23% | Goldman Sachs | Matthew Sykes66% | $16 → $13 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 1391.71% | Morgan Stanley | Tejas Savant50% | $29 → $27 | Maintains | Overweight | Get Alert |
| 05/09/2023 | Buy Now | 1004.97% | RBC Capital | Conor McNamara36% | $22 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 618.23% | Goldman Sachs | Matthew Sykes66% | $16 → $13 | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2023 | Buy Now | 1170.72% | Deutsche Bank | Justin Bowers52% | $25 → $23 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 894.48% | Credit Suisse | Dan Leonard57% | $23 → $18 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 1502.21% | Morgan Stanley | Tejas Savant50% | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 1115.47% | Baird | Catherine Schulte68% | $25 → $22 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 1170.72% | Credit Suisse | Dan Leonard57% | $26 → $23 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 1225.97% | Keybanc | Paul Knight55% | $28 → $24 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 783.98% | Goldman Sachs | Matthew Sykes66% | $18 → $16 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 783.98% | UBS | Dan Brennan65% | $20 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 1281.22% | Deutsche Bank | Justin Bowers52% | → $25 | Initiates | → Buy | Get Alert |
| 12/07/2022 | Buy Now | 1115.47% | RBC Capital | Conor McNamara36% | → $22 | Initiates | → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 894.48% | Goldman Sachs | Matthew Sykes66% | $30 → $18 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1667.96% | Morgan Stanley | Tejas Savant50% | $35 → $32 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 839.23% | B of A Securities | Michael Ryskin46% | $32 → $17 | Downgrade | Buy → Neutral | Get Alert |
| 11/03/2022 | Buy Now | 1336.46% | Credit Suisse | Dan Leonard57% | $34 → $26 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 1446.96% | Keybanc | Paul Knight55% | $35 → $28 | Maintains | Overweight | Get Alert |
| 08/25/2022 | Buy Now | 1778.45% | Credit Suisse | Dan Leonard57% | → $34 | Initiates | → Outperform | Get Alert |
| 08/08/2022 | Buy Now | 1833.7% | Morgan Stanley | Tejas Savant50% | $49 → $35 | Maintains | Overweight | Get Alert |
| 07/14/2022 | Buy Now | 1833.7% | Goldman Sachs | — | $44 → $35 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 2607.18% | Morgan Stanley | Tejas Savant50% | $54 → $49 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 2607.18% | Keybanc | Paul Knight55% | $58 → $49 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Maravai LifeSciences (MRVI) stock?
The latest price target for Maravai LifeSciences (NASDAQ:MRVI) was reported by Morgan Stanley on March 25, 2025. The analyst firm set a price target for $5.00 expecting MRVI to rise to within 12 months (a possible 176.24% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maravai LifeSciences (MRVI)?
The latest analyst rating for Maravai LifeSciences (NASDAQ:MRVI) was provided by Morgan Stanley, and Maravai LifeSciences maintained their equal-weight rating.
When was the last upgrade for Maravai LifeSciences (MRVI)?
The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.
When was the last downgrade for Maravai LifeSciences (MRVI)?
The last downgrade for Maravai LifeSciences Holdings Inc happened on February 26, 2025 when Baird changed their price target from $9 to $3 for Maravai LifeSciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Maravai LifeSciences (MRVI) correct?
While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a maintained with a price target of $7.00 to $5.00. The current price Maravai LifeSciences (MRVI) is trading at is $1.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
